Financials
Half-year Report | Jul. 25, 2024 |
1st Quarter Results | Apr. 25, 2024 |
9M and Q3 2023 results | Nov. 09, 2023 |
Half-year Report | Jul. 28, 2023 |
1st Quarter Results | Apr. 27, 2023 |
AZ 2022 Annual Report XBRL | Feb. 21, 2023 |
Annual Financial Report | Feb. 21, 2023 |
Proxies
Special Business Approved at AGM | Apr. 12, 2024 |
Proxy Form for 2024 AGM | Mar. 07, 2024 |
Notice of AGM | Mar. 07, 2024 |
Notice of AGM | Mar. 07, 2024 |
Special Business Approved at AGM | Apr. 27, 2023 |
Result of AGM | Apr. 27, 2023 |
Notice of AGM | Mar. 22, 2023 |
Ownership Update
Director/PDMR Shareholding | Jun. 12, 2024 |
Director/PDMR Shareholding | May. 15, 2024 |
Director/PDMR Shareholding | Mar. 12, 2024 |
Director/PDMR Shareholding | Mar. 06, 2024 |
Director/PDMR Shareholding | Mar. 06, 2024 |
Director/PDMR Shareholding | Feb. 22, 2024 |
Director/PDMR Shareholding | Dec. 14, 2023 |
Announcements
Total Voting Rights | Sep. 02, 2024 |
Imfinzi approved in US for resectable lung cancer | Aug. 16, 2024 |
Total Voting Rights | Aug. 01, 2024 |
Calquence fixed-duration combo improved 1L CLL PFS | Jul. 29, 2024 |
ODAC reviewed Imfinzi in resectable lung cancer | Jul. 26, 2024 |
Acquisition of Amolyt Pharma completed | Jul. 15, 2024 |
Total Voting Rights | Jul. 01, 2024 |
Prospectuses
AstraZeneca prices a €1.4bn bond offering | Jul. 30, 2024 |
AstraZeneca prices a $5bn bond offering | Feb. 22, 2024 |
AstraZeneca prices a $2.25bn bond offering | Mar. 01, 2023 |
AstraZeneca PLC;AstraZeneca Finance LLC - Base prospectus (debt) | Jun. 15, 2022 |
AstraZeneca prices a EUR800m bond offering | May. 27, 2021 |
AstraZeneca prices a $7bn bond offering | May. 26, 2021 |
AstraZeneca PLC;AstraZeneca Finance LLC - Base prospectus (debt) | May. 24, 2021 |